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Peripartum cardiomyopathy (PPCM) is a systolic heart failure that occurs during the last
month of pregnancy or within 5months after delivery. It is an uncommon disease of
unknown etiopathogenesis and has a very high rate of maternal mortality. Because of
similarity between symptoms of PPCM and physiological discomforts during pregnancy,
the early diagnosis of PPCM presents a major challenge. Since hemodynamic changes
during PPCM can vitally jeopardize the mother and the fetus, patients with severe forms of
PPCM require a multidisciplinary approach in intensive care units. This review summarizes
the current state of knowledge about the diagnosis, monitoring, and the treatment of
PPCM. Having reviewed the recent researches, it gives insight into the new treatment
strategies of this rare disease.
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INTRODUCTION
Even at the beginning of the twenty-first century, heart diseases continue to be the leading cause of
maternal deaths in many countries (1). One of the most severe heart diseases related to pregnancy
is peripartum cardiomyopathy (PPCM).
Peripartum cardiomyopathy is a rare and very serious type of idiopathic cardiomyopathy,
presenting with a left ventricular systolic dysfunction and heart failure during the last month of
pregnancy or up to 5months after delivery, in previously healthy women (2).
This time limit is very important as an exclusion factor for other previously undiagnosed or
preexisting types of cardiomyopathies, which can be unmasked by hemodynamic changes during
pregnancy. Therefore, it is very important to have in mind the fact that a woman without a history
of a heart disease can develop heart failure in the peripartum period.
For the first time, PPCM was defined in 1971 by Demakis et al. who investigated 27 patients
with cardiomegaly, abnormal ECG, and heart failure in the puerperium (3). They defined three
diagnostic criteria for PPCM: the development of heart failure during the last month of preg-
nancy or within 5months after delivery, the absence of determinable etiology for heart failure,
and the absence of heart disease before the last month of pregnancy (3, 4). Recently, echocar-
diographic diagnostic criteria for the left ventricular dysfunction, such as left ventricular ejec-
tion fraction (LVEF) <45%, left ventricular fractional shortening (LVFS) <30% or both, and
left ventricular end-diastolic dimension (LVEDD) >2.7 cm/m2 body surface area, have been
included in the diagnosis of PPCM (5). These criteria made the definition of PPCM more pre-
cise and facilitated differentiation between PPCM and other forms of dilated cardiomyopathy
(Table 1).
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TABLE 1 | Diagnostic criteria for peripartum cardiomyopathy.
Demakis criteria (3, 4) Echocardiographic criteria
Heart failure within last month of
pregnancy up to 5months after delivery
LVEF <45%
Absence of determinable cause for the
heart failure
LVFS <30%
Absence of heart disease before the
last month of pregnancy
LVEDD >2.7 cm/m2 body
surface area
LVEF, left ventricular ejection fraction; LVFS, left ventricular fractional shortening;
LVEDD, left ventricular end-diastolic dimension.
EPIDEMIOLOGY
The incidence of PPCM varies among different countries. Very
high incidence (1:299) is reported in Haiti (6), while in South
Africa, it is 1:1000 (7) and in the USA, 1:2289–4000 (8).
Although it is an uncommon disease, PPCM is associated with
very high maternal mortality rate that can reach 28% after
6months despite the therapy. (9). Those who survive can develop
chronic heart failure and most of them require heart trans-
plantation (9). There are numerous risk factors for PPCM such
as: advanced maternal age, breastfeeding, multiparity, multife-
tal pregnancies, pregnancy induced hypertension, preeclampsia,
and prolonged use of tocolytic therapy (3, 4, 10). The African-
American ethnicity is considered to be a high risk factor for
PPCM (11).
CLINICAL PRESENTATION
Pregnancy is a physiological state accompanied by maternal
hemodynamic changes, during which time, signs and symptoms
could mimic signs of heart failure. Awareness of these changes
is of great importance for early recognition and timely man-
agement of PPCM, which correlate with better prognosis of
these patients. Symptoms of PPCM, such as dyspnea, cough,
fatigue, leg edema, malaise, are very often misinterpreted as
physiological symptoms due to pregnancy. This is the reason
of delayed recognition of PPCM, so at the moment of diag-
nosis patients are presented with NYHA III or IV functional
class (12).
The clinical course of PPCM can vary from mild to extremely
severe heart failure and even cardiogenic shock, which can vitally
jeopardize both the mother and the fetus. Progression to heart
failure can be rapid, very often within few days from the first pre-
sentation of symptoms. Paroxysmal nocturnal dyspnea, nocturnal
cough, hemoptysis, chest pain, and hepatomegaly should raise
suspicion of heart failure (13). Tachycardia, murmurs, pulmonary
rales, and increased jugular pressure can be revealed at physical
examination. Premature ventricular beats, atrial tachycardia, ven-
tricular tachycardia, and cardiac arrest were described in these
patients (14, 15). Left ventricular thrombus and thromboembolic
events can be present (16), and in the worst clinical scenario,
multiorgan failure can occur (17). When considering PPCM, we
should always have on mind a possibility of latent forms. A study
from Haiti reported four women with PPCM without clinical
symptoms, but with echocardiographic findings specific for this
disease (18).
ETIOPATHOGENESIS
Despite numerous researches, the etiopathogenesis of PPCM is
still unknown. There are many hypothesis including myocarditis
(19, 20), genetic succeptibility, fetal microchimerism, and autoim-
mune response (21), which could be an explanation for higher
incidence of PPCM in multiparity (22).
Since the cause of PPCM is unknown, there is still no specific
treatment of this serious disease. Understanding of etiopathogen-
esis could represent a breakthrough in the treatment of PPCM.
From that aspect, studies that investigated inflammation, pro-
lactin, and oxidative stress as a possible cause of PPCM reported
promising results.
In a large prospective study, Sliwa et al. reported significantly
higher levels of inflammatory markers – CRP, IL6, TNFα, and
plasma marker of apoptosis (Fas/Apo-1) in patients with PPCM
than in healthy controls (23, 24). They found positive correlation
between inflammatory markers and LVEDD and LVESD, as well
as inverse correlation between markers and LVEF. Significantly
high value of Fas/Apo-1, as a marker of cardiomyocyte apoptosis
in PPCM patients, was found to be a predictor of mortality.
These researches suggest that inflammation could play a role in
pathogenesis of PPCM. In that case, inflammation markers could
be used in clinical practice as predictors of complications and
mortality. Also, these researches are important from the aspect of
treatment of PPCM and use of TNF inhibitor as a target therapy.
In contrast to these researches, other studies suggest that PPCM
is a consequence of vascular disorders due to cleavage of PRL and
increased oxidative stress.
Hilfiker-Kleiner et al. have found that decreased levels of sig-
nal transducer and activator of transcription 3 (STAT3) in mice
induce decreased activity of manganese superoxide dismutase
(MnSOD) leading to increased oxidative stress. Reactive oxy-
gen species (ROS) accumulation induces cathepsin D activa-
tion, which further cleaves nursing-hormone prolactin of 23 kDa
(23 kDa PRL) into 16 kDa prolactin (16 kDa PRL), which was
proved to have antiangiogenic and proapoptotic effects on car-
diomyocytes (25). Halkein et al. explained antiangiogenic effects
of 16 kDa PRL by expression of micro-RNA146a (26), which
attenuates angiogenesis (26). They found high levels of micro-
RNA146a only in patients with PPCM, but not in those with
dilated cardiomyopathy. They suggested that micro-RNA146a
could be used as a biomarker and therapeutic target for PPCM
(26). In another study, deficiency of VEGF was found to con-
tribute to PPCM (27). Increased levels of PRL, ROS, and 16 kDa
PRL are also found in women with PPCM (25), suggesting that
this mechanism could play a central role in the pathogenesis
of PPCM. The use of bromocriptin, inhibitor of PRL, removed
adverse effects of 16-kDa PRL and prevented PPCM in mice (25).
This highlighted the possibility of its use as a new specific drug in
the treatment of PPCM (Figure 1).
From the clinical point of view, data from these studies may
have an impact on the new treatment strategies of PPCM in the
future.
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FIGURE 1 | Pathogenesis of peripartum cardiomyopathy.
DIAGNOSIS
When considering PPCM, it is very important to have inmind the
fact that a woman without a history of a heart disease can develop
heart failure in the peripartum period. Thus, rising awareness
of PPCM is very important for early diagnosis. Delayed diagno-
sis is followed by higher incidence of complications. When the
diagnosis is made before LVEF decline below 0.35, the mortal-
ity rate approaches 0, and the chance of full recovery is much
greater. Because of similarity in clinical presentation between
PPCM and other types of systolic heart failure, the diagnosis of
PPCM presents a major challenge. It is based on exclusion of
other conditions that could cause heart failure: idiopathic dilated
cardiomyopathy, myocardial infarction, severe preeclampsia, pul-
monary embolism, sepsis, and valvular heart disease. Diagnostic
criteria proposed by Demakis (3) are very important as an exclu-
sion factors for preexisting cardiomyopathies. Themost important
is tomake an early diagnose of PPCM. Initial assessment includes:
history, detailed physical examination, routine blood analysis, and
electrocardiography.
Electrocardiogram patterns are not specific for PPCM. ST-T
wave abnormalities, bundle branch block, atrial fibrillation, and
ventricular tachycardia can be seen (28), as well as myocardial
infarction. Chest X-ray can be done only after delivery, and it can
reveal cardiomegaly, pleural effusion, and pulmonary congestion,
while MRI can be used to distinguish myocarditis and ischemia
as possible causes of PPCM and to estimate segmental and global
myocardial contractility.
The definitive diagnosis of PPCM is based on echocardio-
graphic findings. Echocardiography enables prompt diagnosis and
the evaluation of heart function. Thus, in any case of doubt
or suspicion of heart failure, bed-side echocardiography should
be done as soon as possible. PPCM is presented with systolic
dysfunction, reduced cardiac output, and increased filling pres-
sures (29), while left ventricular dilatation must not be always
present (30). Echocardiographic diagnostic criteria for PPCM
include: EF<45%, LVFS<30% or both, and LVEDD>2.7 cm/m2
body surface area (5). Valvular regurgitation can be present.
In patients with EF 35%, left ventricular thrombus are often
detected (31). In cases of preeclampsia with heart failure, it is very
important to distinguish if it is PPCM in preeclamptic patient or
heart failure as a complication of preeclampsia. In that situation,
echocardiographic findings will distinguish heart failure with
reduced ejection fraction (PPCM) and normal ejection fraction
(preeclampsia). Diastolic dysfunction, preserved ejection frac-
tion, left ventricular hypertrophy, and non-dilated ventricles are
specific for preeclampsia (29, 32).
Biomarkers could be very helpful in early diagnosis of PPCM.
Unfortunately, there are still no specific biomarkers for PPCM.
Brain natriuretic peptide (BNP) and N-terminal portion of pro
BNP (pro-NT BNP) are biomarkers sensitive for heart failure, but
are not specific for PPCM. However, these markers in combina-
tion with echocardiography can be very useful for risk stratifi-
cation and accuracy of diagnosis in patients with asymptomatic
PPCM in cases when levels of BNP and pro-NT BNP are inter-
mediate (33). Several new studies reported promising results
regarding biomarkers in PPCM. Data from these studies reported
significantly higher levels of micro-RNA-146a in patients with
PPCM compared to healthy women and women with dilated car-
diomyopathy (26, 34), which suggest that micro-RNA-146a could
be used as a specific biomarker, and also therapeutic target in
patients with PPCM. However, further studies are needed before
it can be used as a marker in standard clinical practice. Recent
researches in the field of pathogenesis suggest that CRP, Tiff, and
IL 6 could be used as predictors of complications and mortality in
PPCM (23, 24).
Because of the complexity of this disease, which can be fatal for
both mother and the fetus, PPCM should be managed by multi-
disciplinary team. Patients admitted in the ICU require intensive
treatment and hemodynamic monitoring.
MONITORING
Monitoring before and 24 h after delivery is very important
because it is the period of the most prominent hemodynamic
changes. Understanding of physiological hemodynamic changes
during pregnancy is of great importance for interpretation of
hemodynamic parameters of PPCM. Auto transfusion due to
uterine contractions and fluid shifts after delivery could alter
the condition of patients with PPCM, augment the fluid load,
and cause acute heart decomposition. PPCM presents with
decreased cardiac output and increased right and left heart
filling (35).
The choice of monitoring devices depends on the severity of
clinical presentation. Intra-arterial blood pressure should bemea-
sured in severe forms of PPCM followed by intense hypotension.
Because of the risk of potential complications, central venous
catheter and pulmonary artery catheter are not routinely used,
except in cases of severe PPCM. However, in a patient with
dyspnea at rest, severe chest pain, ECG evidence of myocardial
ischemia, severe impairment of myocardial contractility, inva-
sive monitoring with a Swan Gang catheter is justified (36).
The use of continuous non-invasive cardiac output monitoring
(NICOM™) in patient with PPCMwas reported. Since good corre-
lation between cardiac output monitoring with NICOM and with
pulmonary artery catheter has been shown, the authors suggest
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that it can be used as a guide in the treatment of PPCM and also
for early detection of heart decomposition (37).
Tran esophageal echocardiography (TEE) is rarely used in
obstetrics, because it very often requires tracheal intubation and
can be performed only by an experienced practitioner. However,
some authors suggest it as a guide in management of refractory
hypotension and cardiac arrest in obstetric patients (38), thus TTE
could find its place in very severe forms of PPCM.
Tran thoracic echocardiography (TTE) is crucial not only for
diagnosis of PPCM but also for evaluation and monitoring of
the effects of the therapy. It enables the intensives to get non-
invasive serial evaluations of the heart function and structure at
the bedside, without risk of complications. PPCM presents with
decreased EF, systolic dysfunction, decreased LVFS, decreased
cardiac output (5). TTE is the best tool for detecting intracra-
nial thrombi. Cardiac output can be accurately measured using
TTE (39).
MANAGEMENT
The treatment of PPCM does not differ from that of other types
of dilated cardiomyopathy, but the choice of medications depends
on fetal safety during ante partum heart failure and on excretion
of the drug during breastfeeding.
In the cases of acute decompensate heart failure, the initial
management is based onABCs (airway, breathing and circulation)
(40). Patients with pulmonary edema often require supported
ventilation. Since the non-invasive ventilation is accompanied
by the higher risk of aspiration in pregnant women, end tra-
cheal intubation should be considered. Arterial oxygen saturation
95% should be achieved (41). Hemodynamic changes during
PPCM, such as decreased cardiac output, can alter uteroplacental
perfusion and cause fetal distress; thus fetal heart rate monitoring
is mandatory. PPCM is not an indication for delivery except in
cases of hemodynamic unstable patient or rapidly decompensat-
ing patient.
Attention should be paid to the clinical assessment of decreased
cardiac output and hypoperfusion rather than on the exact value
of blood pressure, which must not always indicate hypotension
(42). The treatment of PPCM is based on improvement of hemo-
dynamic status of the patient by decreasing preload and afterload,
and by increasing cardiac contractile force (43, 44).
Angiotensin converting enzyme inhibitors (ACEI) efficiently
reduce afterload, but due to their proven teratogenic effects they
are contraindicated during pregnancy. In antenatal heart failure,
vasodilatators such as hidralazine and nitroglycerin can be safely
used instead of ACEI and ARB, but should be carefully titrated if
systolic blood pressure is between 90 and 110mm Hg (41). ACEI
can be used after delivery. Benazepril, captopril, and enalapril
were tested in nursing women and their use has proven to be safe
for babies (45). ACEI improve survival of patients with PPCM
(46). Patients who cannot tolerate ACEI can be treated with
angiotensin-receptor blockers (ARB) (47).
Sodiumnitroprusside should be avoided because of thiocyanate
toxicity. Loop diuretics reduce preload and fluid overload and
relieve symptoms of PPCM, but should be used with caution
because they can cause hypotension, uterine hypoperfusion and,
consequently, fetal distress.
Digoxin has positive inotropic effects and improves ejection
fraction in combination with vasodilatators. It can be safely
used during pregnancy and breastfeeding (48). In cases of severe
decompensated antenatal heart failure with hypotension, dobu-
tamine and dopamine are the drugs of choice.
The use of levosimendan in PPCM is still controversial. There
are case reports about the successful use of levosimendan (49, 50),
but randomized controlled trials are needed to prove its positive
effects on outcome in PPCM.
Beta blockers are indicated in PPCM, and some authors suggest
that they should be continued for at least 1 year (51). Beta-1
blockers are preferred, as they do not interfere with uterine tone,
while beta non-selective blockers should be avoided because of
anti-tocolytic effects. Alpha and beta blocker, carvedilol, has been
shown to be very effective in PPCM (44).
Uterotonics should be very carefully used in PPCM. Oxytocin
decreases systemic vascular resistance, compensatory increases
heart rate, and can cause coronary vasoconstriction, so is poorly
tolerated in state of LV dysfunction. Therefore, it should be
slowly titrated. Ergometrine causes coronary and pulmonary
vasoconstriction, and should be avoided in PPCM (52). Postpar-
tum analgesia is very important in patients with PPCM. Pain-
induced sympathetic activation leads to tachycardia and increase
in afterload, which further compromise heart function. Therefore,
epidural analgesia is preferred for labor, and it can be continued
in the ICU. Thromboembolic events are common in PPCM. It
is recommended that patients with LVEF <35% should receive
anticoagulation therapy (53).
Arrhythmias are not rare in PPCM. Refractory life-threatening
arrhythmias in patients with poor left ventricular function are
indications for implantable cardioverter defibrilator (53). Patients
who are hemodynamically unstable despite intensivemedicamen-
tous treatment may need intraaortic balloon counterpulsation
pump, left ventricular assist devices, and in the most severe cases,
heart transplantation (2). Patients with PPCM can develop heart
failure in subsequent pregnancies.
NEW TREATMENT STRATEGIES
Data from researches related to the pathogenesis of PPCM were
the basis for further investigations in the field of the treatment of
PPCM.
Pentoxifylline
Pentoxifylline, an inhibitor of TNFα, was evaluated in patients
with PPCM. Significantly higher levels of CRP, IL6, TNFα were
reported in patients with PPCM than in healthy controls having
suggested that inflammation could be a cause of PPCM (24).
Sliwa et al. have studied the effects of pentoxifylline on outcome
in patients with PPCM (9) and found that patients who received
pentoxifylline as an addition to standard therapy had better out-
come than thosewhowere treated onlywith standard therapy. The
role of pentoxifylline in the treatment of PPCM requires further
evaluation.
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Bromocriptine
New researches by Hilfiker-Kleiner et al. suggested that oxida-
tive stress and the cleavage of PRL may play a central role in
the pathogenesis of PPCM (25). Based on these data, one pilot
study in South Africa evaluated the effects of bromocriptine
in patients with PPCM (54). The results of this study showed
that patients who received bromocriptine in addition to standard
therapy improved LVEF and clinical outcome. This suggests that
bromocriptine could be used as a new specific therapy for PPCM.
However, large randomized trials are needed before it can be used
for the treatment of PPCM in clinical practice.
CONCLUSION
Peripartum cardiomyopathy is a rare and very severe disease.
Symptoms of PPCM canmimic symptoms of a normal pregnancy,
which is the most common reason of delayed diagnosis. Delayed
diagnosis almost always leads to severe forms of PPCM. Thus,
attention should be paid on early diagnosis and treatment, which
are crucial for better outcome.We should always have in mind the
fact that the woman without previous heart disease can develop
heart failure. Therefore, increased awareness of PPCM as well as
high level of suspicion are themost important steps in establishing
the early diagnosis. Early symptoms such as dyspnea, fatigue,
leg edema, and malaise, which are often misinterpreted as phys-
iological, should not be underestimated. Paroxysmal nocturnal
dyspnea, nocturnal cough, and chest pain should raise suspicion of
heart failure. PPCM is the diagnosis of exclusion. TTE is crucial
not only as a diagnostic tool but also as a bedside non-invasive
hemodynamicmonitoring device. Treatment of PPCM is basically
the same as for other non-ischemic cardiomyopathy, with the
limitation concerning fetal development and wellbeing. The task
for future studies is to find the cause of PPCM, and the specific
biomarker of this disease, which would significantly contribute to
early diagnosis and specific treatment of PPCM. In that context,
studies that investigate inflammation, prolactin, and oxidative
stress give promising results.
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